Apolipoprotein E and Alzheimer's disease

被引:41
|
作者
Troutwine, Benjamin R. [1 ,2 ]
Hamid, Laylan [2 ]
Lysaker, Colton R. [2 ,3 ]
Strope, Taylor A. [2 ,3 ]
Wilkins, Heather M. [1 ,2 ,3 ]
机构
[1] Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66160 USA
[2] Univ Kansas, Alzheimers Dis Ctr, Kansas City, KS 66160 USA
[3] Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA
基金
美国国家卫生研究院;
关键词
Apolipoprotein E; Alzheimer's disease; Mitochondria; Neuroinflammation; Amyloid beta; Tau; AMYLOID-BETA-PEPTIDE; ISOFORM-DEPENDENT MANNER; APOE EPSILON-4 ALLELE; E POLYMORPHISM; E GENOTYPE; CYTOCHROME-OXIDASE; NEURITE OUTGROWTH; MOUSE MODEL; LIPOPROTEIN RECEPTORS; POSTERIOR CINGULATE;
D O I
10.1016/j.apsb.2021.10.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Genetic variation in apolipoprotein E (APOE) influences Alzheimer's disease (AD) risk. APOE epsilon 4 alleles are the strongest genetic risk factor for late onset sporadic AD. The AD risk is dose dependent, as those carrying one APOE epsilon 4 allele have a 2-3-fold increased risk, while those carrying two epsilon 4 alleles have a 10-15-fold increased risk. Individuals carrying APOE epsilon 2 alleles have lower AD risk and those carrying APOE epsilon 3 alleles have neutral risk. APOE is a lipoprotein which functions in lipid transport, metabolism, and inflammatory modulation. Isoform specific effects of APOE within the brain include alterations to A beta, tau, neuroinflammation, and metabolism. Here we review the association of APOE with AD, the APOE isoform specific effects within brain and periphery, and potential therapeutics. (c) 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:496 / 510
页数:15
相关论文
共 50 条
  • [41] Apolipoprotein E and Alzheimer disease
    Huang, YD
    [J]. NEUROLOGY, 2006, 66 : S79 - S85
  • [42] Apolipoprotein E and Alzheimer disease
    Growdon, JH
    [J]. ARCHIVES OF NEUROLOGY, 1998, 55 (08) : 1053 - 1054
  • [43] Apolipoprotein E and Alzheimer disease
    Roses, AD
    Saunders, AM
    Corder, EH
    Risch, NJ
    Haines, JL
    PericakVance, MA
    Han, SH
    Einstein, G
    Hulette, C
    Schmechel, DE
    Goedert, M
    Jakes, R
    Dong, LM
    Weisgraber, KH
    Holsti, M
    Huang, D
    Strittmatter, WJ
    [J]. PRECLINICAL AND CLINICAL STRATEGIES FOR THE TREATMENT OF NEURODEGENERATIVE, CEREBROVASCULAR AND MENTAL DISORDERS, 1996, 11 : 187 - 197
  • [44] Apolipoprotein E genotype, vitamin E, and Alzheimer's disease prevention
    Huebbe, P.
    Rimbach, G.
    [J]. JOURNAL OF APPLIED BOTANY AND FOOD QUALITY, 2008, 82 (01): : 69 - 75
  • [45] Apolipoprotein E, Alzheimer's disease and Down's syndrome - Reply
    Deb, S
    Williams, J
    Owen, MJ
    [J]. BRITISH JOURNAL OF PSYCHIATRY, 2000, 177 : 469 - 470
  • [46] Apolipoprotein E: A pharmacogenetic target for the treatment of Alzheimer's disease
    Poirier, J
    [J]. MOLECULAR DIAGNOSIS, 1999, 4 (04): : 335 - 341
  • [47] Clinical correlates of apolipoprotein E in Alzheimer's disease - Reply
    Hyman, BT
    GomezIsla, T
    Growdon, JH
    [J]. ANNALS OF NEUROLOGY, 1996, 40 (04) : 689 - 689
  • [48] Targeting Apolipoprotein E for Alzheimer's Disease: An Industry Perspective
    Suidan, Georgette L.
    Ramaswamy, Gayathri
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (09)
  • [49] Apolipoprotein E and Alzheimer's disease: A review of recent studies
    Higgins, GA
    Large, CH
    Rupniak, HT
    Barnes, JC
    [J]. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1997, 56 (04) : 675 - 685
  • [50] Apolipoprotein E genotyping in the diagnosis of Alzheimer's disease - Reply
    Bird, TD
    [J]. ANNALS OF NEUROLOGY, 1995, 38 (06) : 970 - 970